We have developed an individualized melanoma vaccine based on transfection of autologous dendritic cells (DCs) with autologous tumor-mRNA. Dendritic cells loaded with complete tumor-mRNA may generate an immune response against a broad repertoire of antigens, including unique patient-specific antigens. The purpose of the present phase I/II trial was to evaluate the feasibility and safety of the vaccine, and the ability of the DCs to elicit T-cell responses in melanoma patients. Further, we compared intradermal (i.d.) and intranodal (i.n.) vaccine administration. Twenty-two patients with advanced malignant melanoma were included, each receiving four weekly vaccines. Monocyte-derived DCs were transfected with tumor-mRNA by electroporation, matured and cryopreserved. We obtained successful vaccine production for all patients elected. No serious adverse effects were observed. A vaccine-specific immune response was demonstrated in 9/19 patients evaluable by T-cell assays (T-cell proliferation/interferon-g ELISPOT) and in 8/18 patients evaluable by delayed-type hypersensitivity (DTH) reaction. The response was demonstrated in 7/10 patients vaccinated intradermally and in 3/12 patients vaccinated intranodally. We conclude that immuno-gene-therapy with the described DC-vaccine is feasible and safe, and that the vaccine can elicit in vivo T-cell responses against antigens encoded by the transfected tumor-mRNA. The response rates do not suggest an advantage in applying i.n. vaccination. Cancer Gene Therapy (2006) 13, 905-918.
Introduction
Currently, an effective systemic treatment for metastatic malignant melanoma is not available. 1 The 5-year survival for melanoma patients with disseminated disease is about 6%, with a median survival of 7.5 months. 2 The observation of spontaneous immune responses in melanoma patients have inspired various efforts of immune therapy. 3, 4 To date, most melanoma vaccines have made use of defined melanoma antigens like MAGE-1 and -3, MART-1/Melan A and gp100. [5] [6] [7] [8] [9] Although promising responses have been obtained, the defined melanoma antigens are not essential for tumor survival, and genetic alterations may lead to tumor escape. The use of peptide cocktails or allogenic tumor cell lines as source of antigen may initiate broader immune responses. [10] [11] [12] However, as has been argued, the majority of tumor antigens may be unique patient-specific antigens, caused by incidental mutations that are specific for each patient. [13] [14] [15] [16] Aiming for individualized therapy, we have developed a melanoma vaccine based on transfection of autologous dendritic cells (DCs) with complete autologous tumor mRNA.
Dendritic cells are considered the most potent antigenpresenting cells (APCs), 17 and DC-based vaccines are being investigated in several cancer forms, including malignant melanoma. 10, [18] [19] [20] [21] [22] By our strategy, we intend to make the DCs present a wide spectrum of antigens that are relevant to each patient's tumor. The tumor-RNA approach overcomes the requirement for defined human lymphocyte antigen (HLA) alleles and for expression of identified antigens by the tumors. We have previously reported effective methods for RNA-transfection by square wave electroporation 23 and for generation of clinical grade DCs. 24 Recently, we reported a full-scale preclinical evaluation of the melanoma DC-vaccine. 25 In the preclinical evaluation, we established the methods applied in the present trial for full-scale vaccine produc-tion and for monitoring of immune responses. Further, we demonstrated that tumor-mRNA transfected DCs (tDCs) were capable of inducing in vitro T-cell responses specific for antigens encoded by the transfected mRNA. Both CD4 þ and CD8 þ T-cell responses were demonstrated.
To our knowledge, the clinical trial reported here is the first melanoma DC-vaccine trial based on autologous tumor-mRNA as the source of antigen. The experience with tumor-RNA vaccines is also limited in other cancer forms. To date have been reported a pilot vaccination of a patient with lung cancer 26 followed by three phase I trials, in renal cancer, 27 pediatric brain cancer 28 and neuroblastoma. 29 The phase I studies all applied vaccination with immature DCs that were transfected by simple coincubation with tumor-RNA.
Here, we report the results of an immuno-gene-therapy trial conducted in 22 patients with advanced malignant melanoma. The aim of the phase I/II trial was to study the safety and feasibility of individualized therapy with the described tDC-vaccine, and to evaluate the ability of the tDCs to elicit in vivo T-cell responses in the advanced melanoma patients. Further, we compared intranodal (i.n.) and intradermal (i.d.) administration of the vaccine. The results suggest that therapy with the described melanoma DC-vaccine is feasible and safe, and that T-cell responses specific for transfected antigens are induced in vivo in about 50% of the patients.
Materials and methods

Patient inclusion and exclusion
According to the inclusion criteria, only patients with histologically confirmed, advanced metastatic malignant melanoma, and evidence of disease progression, were eligible for the trial. Age 418 years, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 and adequate hematologic, renal and hepatic function were required. Any prior radiotherapy or chemotherapy had to be completed a minimum of 4 weeks prior to study entry. The final decision on including a patient was made after preparation of the individualized vaccine. The trial was approved by the Norwegian Medicines Agency, the Norwegian Department of Health (Gene Therapy Board), the Regional Committee for Medical Research Ethics and the Hospital Internal Review Board. It was performed in compliance with the World Medical Association Declaration of Helsinki. Written informed consent was obtained from all patients.
Tumor material and RNA extraction/evaluation Tumor biopsies were collected at The Norwegian Radium Hospital and stored on 'RNA Later' solution (SigmaAldrich, St Louis, MO, USA), according to the manufacturer's protocol. Extraction of autologous tumor-RNA was performed as a two-step procedure, as previously described. 25 First, total-RNA was extracted by use of Trizol (Invitrogen Life Technologies, Carlsbad, CA). Then mRNA was purified by use of polyT-coated magnetic beads (Genoprep mRNA Beads, Qiagen, Hilden, Germany). The quality of all RNA preparations was controlled by electrophoresis on agarose gels stained by Gelstar (Cambrex Bio Science, Verviers, Belgium). For 16 patients, the RNA samples were also evaluated on an Agilent Bioanalyser instrument (Agilent Technologies, Palo Alto, CA), as previously described. 25 The RNA concentration, rRNA percentage and mRNA content were estimated, according to the manufacturer's protocol.
From some patients, pending on available tumor material not needed for mRNA extraction, we also attempted to generate autologous melanoma cell lines. However, we only succeeded in patients that were subsequently not included in the trial, due to rapid disease progression, and a few trial patients that did not respond to the vaccine.
Dendritic cell generation, transfection and phenotyping Dendritic cell generation was performed as previously described. 24, 25 Briefly, peripheral blood mononuclear cells (PBMCs) were harvested by leukapheresis. Monocytes were enriched by immunomagnetic depletion of T cells and B cells and then cultured for 5 days in CellGro DC medium (CellGenix, Freiburg, Germany) with granulocyte-macrophage colony-stimulating factor (GM-CSF; 2500 U/ml) (Leucomax; Schering-Plough, Kenilworth, NJ) and interleukin-4 (IL-4; 1000 U/ml) (CellGenix). The immature DCs were transfected with RNA and then cultured for 2 more days with cytokines facilitating maturation: IL-1b (10 ng/ml), IL-6 (1000 U/ml), tumor necrosis factor a (TNFa; 10 ng/ml) (CellGenix) and prostaglandin E 2 (1 mg/ml) (Sigma-Aldrich). Monocytes/ DCs were cultured in Teflon bags (CELLGenix). Finally, matured DCs were frozen to À801C and transferred to liquid nitrogen. The RNA transfection was performed by square wave electroporation, as described earlier. 23, 25 To obtain adequate control DCs for T-cell assays, a fraction of immature DCs from each patient was mocktransfected, that is, electroporated without mRNA. Through DC generation, we evaluated the cell quality and yield by flowcytometry, automated counting, sterility and viability testing, as previously described. 24 Dendritic cell viability was also measured (Trypan blue staining) in all vaccine batches immediately before injection, that is, after freezing/thawing.
The following panel of fluorescein isothiocyanate (FITC)-and phycoerythrin (PE)-conjugated antibodies was applied for flowcytometry phenotyping of mature DCs: anti-human CD1a, CD14, CD19 (Dako Cytomation, Glostrup, Denmark); CD3, CD16/CD56, CD80, CD86, HLA-DR (Becton Dickinson, San Jose, CA); CD83 (Immunotech, Marseilles, France). FITC and PE-conjugated IgG1 and IgG2a antibodies (Dako Cytomation) of irrelevant specificities were included as negative controls. Cells distributed like DCs were gated in forward/sideward scatter (FSC/SSC) dotplots and analyzed further for phenotypic markers, as described earlier. 25 The cells outside of the DC-gate mainly consisted of T cells and NK cells.
Vaccination
Each patient received four weekly injections. Each vaccine batch generally contained 20 Â 10 6 DCs. If required, because of lower DC yield, the number of DCs per batch was adjusted (Table 1) . Twelve patients had the DCs injected by ultrasound-guidance into an inguinal lymph node. The other 10 patients were vaccinated by i.d. injection 10 cm below the inguinal ligament, that is, in a region where the lymphatic vessels drain to inguinal lymph nodes. The patients were allocated to the i.n. and i.d. vaccine group, according to the order of inclusion; the first five and last five patients included were vaccinated i.d.
T-cell cultures and assays
Peripheral blood mononuclear cells were obtained prior to vaccination, after 5 weeks (i.e. 2 weeks after last vaccine) and after 13 weeks. The PBMCs were isolated, frozen and cultured essentially as previously described. 25 Thawed PBMCs were stimulated twice with tDCs. Interleukin-2 (10 U/ml) was supplemented from day 3 after the second stimulation, or earlier if necessary for the T cells to survive. For each patient, the T cells from preand postvaccination samples were cultured under identical conditions.
The T-cell proliferation assays were performed essentially as described earlier, 25 on freshly thawed PBMCs, and after one and two in vitro stimulations. The assays were performed in triplicates or hexaplicates. Irradiated tDCs and mock-transfected DC controls (mockDCs) were used as APCs. Negative controls with T cells only and positive controls with T cells þ mockDCs þ Staphylococcus enterotoxin C 3 (SEC 3 ; Toxin Technologies) were included. The SEC 3 -stimulated T-cell controls were generally highly proliferative.
The interferon-g (IFNg) ELISPOT assays were performed essentially as described previously. 25 Responder T cells were seeded as duplicates at three different concentrations and stimulated with tDCs or mockDCs. Negative controls with T cells only and positive controls with T cells þ mockDCs þ SEC 3 were included. The SEC 3 -stimulated control wells were generally highly positive. For all patients except M02, the spots were enumerated using an automated ELISPOT counter (Carl Zeiss Vision, Oberkochen, Germany) at The National Hospital, Oslo.
Bioplex cytokine assay
Supernatants were harvested from triplicate T-cell cultures at day 3 and analyzed by Bioplex assays (Bio-Rad, Laboratories, Hercules, CA), according to the manufacturers protocol. We analyzed the supernatants for IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IFNg, TNFa, GM-CSF, macrophage inflammatory protein 1b (MIP-1b) and monocyte chemoattractant protein 1 (MCP-1) ( Table 2) .
Delayed-type hypersensitivity reaction
The delayed-type hypersensitivity (DTH)-reactions were recorded for tDCs and mockDC controls injected at separate sites after completion of the vaccination schedule. For i.d. vaccinations, the DTH reaction to each vaccine was registered. The DTH was measured as diameter of the erythema 48 h after injection. The DTH was scored as moderately/strongly positive if the erythema diameter for tDCs was X10 mm larger than for the mockDCs. Erythema differences of 5-10 mm were considered weakly positive.
Clinical monitoring
Adverse events were graded according to the National Cancer Institute common toxicity criteria (NCI-CTC). The clinical investigator described the relationship to treatment as probable, suspected, unlikely or not related. Adverse events were considered as being related to treatment if the relationship was reported as probable or suspected. Objective tumor response was assessed by clinical examination and computed tomography (CT) scans prior to start of vaccination and after 3 months. The tumor response was classified according to the Response Evaluation Criteria in Solid Tumors (RECIST). 30 
Statistical analysis
To determine if a T-cell response was tDC-specific, we compared the T-cell proliferation counts/ELISPOT counts/cytokine secretion elicited by tDCs, by mockDCs and by T cells only. For statistical analysis of T-cell proliferation assays and Bioplex assays, we applied oneway analysis of variance (ANOVA), followed by StudentNewman-Keuls (SNK) test (SPSS for Windows, SPSS Inc.). In the ELISPOT assays, the different T-cell concentrations were analyzed together by two-way ANOVA (SPSS), followed by SNK test. Proliferation and ELISPOT counts are displayed as mean counts per minute (c.p.m.)7standard error of the mean (s.e.m.). The Mann-Whitney test (SPSS) was applied for comparative analysis of vaccine responders and nonresponders with regard to mRNA concentration at electroporation and fraction of CD83 þ DCs. Wilcoxon signed-rank test for paired variables (SPSS) was used for comparing the paracortex width before and after i.n. vaccinations. The groups vaccinated by i.d. and i.n. injection were compared by Fischers exact test (SPSS) with regard to immune reponse rate. Generally, a response or correlation was considered significant only if Po0.05. All P-values given are two-tailed, exact values.
Results
Patient characteristics and vaccine production
The vaccine trial was conducted on 22 patients with advanced malignant melanoma. Table 1 shows patient characteristics at time of study entry. As shown, 21/22 patients had stage IV disease and 16/22 patients were classified into metastasis category M1C due to visceral metastases and/or elevated serum levels of lactate dehydrogenase.
We performed leukapheresis on 24 melanoma patients and for all these patients obtained DCs of acceptable quality and quantity for vaccination. Two patients could i Immune response in T-cell assays and/or DTH, generated by the vaccine. Patients M09 and M15 were considered not conclusive ('NC'). Details are given in Table 3 . j Survival (months), from start of vaccination to September 1st 2005 (+) or to mors. k Survival (months), from first time diagnosed progression to the M categories recorded at inclusion. l NM: not measured (tumor-mRNA evaluated only on gel electrophoresis). m Classified as M1C due to elevated serum levels of lactate dehydrogenase (LDH).
not be included in the vaccine trial due to rapid disease progression. The DC evaluation results are summarized in Table 1 . There were no substantial differences between tDCs and mockDCs from the same patient neither with regard to DC viability nor phenotype (data not shown). Comparing the different patients, there was considerable variation in the DC expression of maturation marker CD83 (mean 62%; range 18-99%). However, the percentage of CD86 þ and HLA-DR þ cells was generally high (mean CD86 þ DCs ¼ 97%; mean HLA-DR þ DCs ¼ 92%). Even the CD83 À DC population was positive for CD86 and HLA-DR, but the expression was higher in the CD83
þ DCs, as previously described. 25 The expression of CD83 on DCs is generally assumed to indicate efficient APC-function. We therefore compared the CD83 expression in the vaccine immune responders to the nonresponders, as classified by combining T-cell assays and DTH reactions (Table 3 ). Statistical analysis (n ¼ 20) did, however, not indicate any correlation between CD83-expression and vaccine response (P ¼ 0.85). Tumor-RNA was extracted from biopsies taken from 26 melanoma patients, and mRNA of satisfactory quality was obtained from all these patients (data not shown). A priori we reasoned that a high mRNA concentration at transfection may be beneficial and decided to use all mRNA available for each patient. The RNA evaluation (Table 1) demonstrated that the mRNA-concentration varied considerably (mean 79 mg/ml, range 4-608 mg/ml).
We compared the mRNA concentrations measured for the vaccine immune responders and nonresponders (Tables 1 and 3 ) by statistical analysis (n ¼ 14). No significant difference was demonstrated (P ¼ 0.57).
The efficiency of transfection was repeatedly evaluated through the trial, by electroporation of DCs with mRNA coding for green fluorescent protein (GFP). As previously reported, 23, 25 we consistently observed a high efficiency of transfection, with 90-99% GFP positive cells (data not shown).
Safety
The vaccine was well tolerated, both when given by i.d. and i.n. injection. No treatment-related grade III-IV toxicity was observed. Nine patients reported minor symptoms (grade I) related to a local inflammatory reaction at the injection site, and seven patients reported flu-like symptoms (six grade I, one grade II). One patient experienced pain in a tumor (grade II), and one patient developed vitiligo (grade I). A few patients developed anemia or hypoalbuminemia, but this was considered probably to be related to disease progression and not to treatment. In all, blood tests revealed no treatmentrelated hematologic, renal or hepatic toxicity.
Intranodal vaccination
At each i.n. vaccination, the receiving lymph node was evaluated by ultrasound ( Figure 1a) . We found that the lymph node macro-architecture remained well preserved The concentration of multiple cytokines in supernatants from T cell cultures was measured by Bioplex (patients M05, M09, M19). All T cells/PBMCs tested were from postvaccination samples (T 5 and PBMC 5 ). For patients M05 and M09, we tested T cells previously stimulated in vitro. For patient M19 we tested freshly thawn PBMCs. T cells (T) were stimulated with tDCs or mockDCs. Supernatants were collected from triplicate cell cultures, each supernatant kept separate through T-cell stimulation and Bioplex assays. The mean concentration for all detected cytokines is displayed in Table 2 . Concentrations significantly higher (Po0.05) in tDC than mockDCcontrols are shown in bold font. No significant secretion of IL-4, IL-10 or IL-12 were detected (data not shown).
in all patients through the vaccination period. The external capsule, the cortex/paracortex region and the medulla all appeared intact. Furthermore, we observed an increase in the width of the cortex/paracortex region (i.e. the lymphocyte area) in most patients after vaccination (Figure 1b ). Statistical analysis, on the entire group of patients measured, also demonstrated a significant mean increase in the cortex/paracortex width (P ¼ 0.008).
Immune response T cells from pre-and postvaccination samples were tested for T-cell proliferation to tDCs and mockDC controls. The proliferation assays were performed for all patients subject to availability of cells, that is, in 19 out of 22 patients (Table 3 ). In 10/19 patients, a significantly higher proliferation to tDCs than mockDC controls (Po0.05) was demonstrated, indicating that a component of the responding T cells was specific for antigens encoded by the transfected tumor-mRNA. The tDC-specific response was demonstrated for three patients in freshly thawed PBMCs, in four more patients after one in vitro stimulation and in another three patients after two stimulations. In Figure 2a are displayed, for all these 10 patients, the proliferation counts after the minimum in vitro stimulations required for tDC-specific proliferation. i.n.
a DTH: tDC 4 , DTH to tDCs after last vaccination. mockDC 4 , DTH to mockDC controls after last vaccination. tDC 1 , DTH to tDCs after first vaccination.
b Combined immune response (vaccine generated). Patient M15 was considered not conclusive (NC) because the DTH was weakly positive, and the T-cell assay not done. Patient M09 was considered not conclusive because strong T-cell proliferation responses were detected in both pre-and postvaccination samples. f Survival (months), from first time diagnosed progression to the M categories specified in Table 1 . g moderate tDC-specific T-cell response in prevaccination samples, considerably increased in postvaccination samples. h Complete regression of a subcutaneous tumor and partial regression of a lymph node tumor, but persistence of a suprarenal metastasis.
i High tDC-specific response in prevaccination samples, unchanged in postvaccination samples.
In seven patients the tDC-specific proliferation was detected only in postvaccination samples, which were obtained at week 5 (2 weeks after the last vaccine). A tDC-specific response in prevaccination samples was demonstrated for one patient (M02) in freshly thawed PBMCs and for two more patients (M07 and M09) after one in vitro stimulation (Figure 2a) . As in vitro generation of new T-cell responses against autologous antigens generally requires several restimulations, the data suggest that not only M02 but also M07 and M09 had spontaneous in vivo immune responses against antigens encoded by the transfected tumor-mRNA. For patients M02 and M07, the tDC-response was considerably stronger in postvaccination samples, suggesting a booster effect of the vaccine. For patient M09, a strong response was demonstrated even in prevaccination samples, remaining unchanged after vaccination.
We repeatedly observed increased T-cell reactivity to stimulation with mockDC controls after vaccination. As shown in Figure 2b , we observed increased proliferation even in freshly thawed PBMCs for 6/19 patients (M04, M05, M06, M07, M19 and M22). Similar responses were also observed in IFNg ELISPOT assays and DTH recordings. HLA-blockage by use of monoclonal antibodies resulted in complete blockage of T-cell proliferation to tDCs or mockDCs compared to T cell only controls, as previously shown in the preclinical evaluation. 25 To study the endurance of the tDC-response, we collected PBMCs at week 13, that is, 10 weeks after the last vaccine. Week-13 PBMCs were available from 6/10 patients in which a tDC-specific T-cell response had been demonstrated. In 4/6 patients, a significant tDC-specific response was still detected at week 13. The proliferation counts (Figure 2c ) suggested that the response in one patient (M03) was lower at week 13 than week 5, while the response appeared to be retained at the same level in the other three responding patients (M16, M18 and M19).
Interferon g ELISPOT assays were generally performed only on freshly thawed PBMCs, not after in vitro stimulations, as the assay primarily was included to reflect the frequency of tDC-specific T cells in peripheral blood. A tDC-specific IFNg ELISPOT response was demonstrated for all three patients with a proliferation response in freshly thawed PBMCs (Figure 3a-c) . The ELISPOT for M19 was though only performed after an in vitro stimulation. Furthermore, tDC-specific ELISPOT responses were demonstrated 10 weeks after the last vaccine for patients M03 and M18 (Figure 3d-e) . The remaining ELISPOT assays were negative, in accordance with the proliferation results for freshly thawed PBMCs described above.
Human lymphocyte antigen-typing revealed that only one of the immune responders was HLA-A2 positive. In an attempt to study if a component of the response to tDCs was directed against common melanoma antigens, we tested this patient using HLA-A2 restricted peptides derived form gp100, tyrosinase, Melan A/MART-1 and MAGE-3. No response was detected (data not shown).
In T-cell cultures from three immune responders, we performed extensive characterization of the cytokine profile by use of Bioplex assays (Table 2) . Interleukin-2 secretion was detected only in freshly thawed PBMCs from patient M19. We demonstrated tDC-specific production of IFNg and TNFa in T-cell cultures from patient M05. While IL-4 and IL-10 were not detected for any patient, the Th2-cytokines IL-5 and IL-13 were demonstrated in all measured cultures. Secretion of the proinflammatory chemokines MCP-1 and MIP-1b, specific to tDC-stimulation, was detected in T-cell cultures from patients M05 and M09, respectively.
The DTH results are shown in Table 3 . In five patients, we detected tDC-specific, vaccine generated DTH reactions that we considered to be moderately/strongly positive, designated ' þ ' in Table 3 . In three more patients, we measured vaccine generated DTH reactions considered to be weakly positive, designated '( þ )' in Table 3 .
Based on both the in vitro T-cell assays and the DTH reactions, 10/22 patients were considered as immunological vaccine responders, 10/22 as nonresponders and 2/22 as not conclusive (Table 3) . Excluding the two patients regarded not conclusive, a response was obtained in 7/10 patients vaccinated intradermally, compared to 3/10 patients vaccinated intranodally. Statistical analysis (n ¼ 20) did not demonstrate a significant difference between the two groups (P ¼ 0.18).
Clinical response
The survival to date for all trial patients is listed both in Tables 1 and 3 . As shown, three patients are still alive. Based on the M-category at study entry, we registered the point of time when the patients had first been diagnosed with progression to their respective M-categories. Calculated from the time of progression, the mean survival to date is 16.1 months for the entire vaccine group, 14.6 months for the stage IV patients and 12.3 months for the M1C patients. Calculated from the start of vaccination, the mean survival to date is 12.3 months in the entire vaccine group, 11.1 months among the stage IV patients and 8.1 months for the M1C patients. Interestingly, all four patients surviving more than 20 months (from start of vaccination) belong to the immunological vaccine responders.
The vaccine trial reported here is a nonrandomized study. Accordingly, the survival time for the trial patients cannot be directly compared to a control group. However, we found it interesting to obtain accurate information on the prognosis of these advanced melanoma patients, when treated at the same hospital in the same period. We therefore recorded the survival time for all stage IV melanoma patients treated at the hospital in the period of the vaccine trial. The patients in this reference group received the same standard treatment as the trial patients, but no vaccine. The nonvaccinated patients were agematched to the trial patients and classified as M1A (n ¼ 33), M1B (n ¼ 28) or M1C (n ¼ 47). As in the trial, patients with brain metastases were excluded. The observed mean (median) survival times were 5.8 (3.9) months for M1C patients, 10.8 (8.1) months for M1B and 12.4 (9.5) months for M1A. To date, the fractions of patients alive are 1/47 (M1C), 5/28 (M1B) and 7/33 (M1A). In the phase I/II trial, the M1C group (n ¼ 16) is the only prognostic category large enough for being analyzed as a group. Interestingly, the data given above show that the M1C patients in the trial survived longer than the nonvaccinated M1C patients, both when the survival time is calculated from the time of progression and from the start of vaccination.
The tumor response at week 13 for all trial patients is listed in Table 3 . Prior to study entry, all 22 patients had evidence of disease progression, although one patient (M05) had all detected tumors removed before vaccination. The majority (18/22 patients) also demonstrated progressive disease (PD) after vaccination. Two patients, M03 and M12, had stable disease (SD) at week 13, while two patients had no remaining tumors (after surgery) and were thus not evaluable (NE).
For patient M03, we observed complete and lasting regression of a subcutaneous metastasis (3 Â 4 cm 2 ), accompanied by inflammatory signs in the tumor. Moreover, the CT scans at week 13 demonstrated partial regression of a metastatic cervical lymph node in the patient, while a suprarenal metastasis remained stable. Furthermore, we demonstrated a strong tDC-specific T-cell response for the patient both in proliferation and ELISPOT assays, even on freshly thawed PBMCs (Figures 2a and 3b) . The response was also demonstrated in week 13 samples (Figures 2c and 3d) . In addition, the patient had a strong tDC specific DTH response (Table 3) . However, after some time, patient M03 again developed PD. The patient survived for 23 months after the start of vaccination.
For patient M05, the only stage III patient, we demonstrated a tDC-specific response both in DTH measurements and in T-cell proliferation and Bioplex assays. The patient developed vitiligo and remained free of disease for 2 years. He then developed recurrent disease and died 37 months after the start of vaccination.
Discussion
By our vaccine strategy, we aim at inducing immune responses against a broad repertoire of tumor-associated antigens, expressed in the melanomas of each individual patient. The mRNA can encode multiple epitopes, and presentation on different HLA alleles may result in recruitment of a wide spectrum of T-cell clones. The approach chosen however also has certain disadvantages. Restricted amounts of tumor-mRNA are available, and the mRNA will be extensively diluted during full-scale transfection. At electroporation only minute amounts of mRNA coding for each antigen will reach the DC cytosol. In spite of these concerns, the preclinical full-scale evaluation demonstrated that the tDCs are capable of inducing in vitro T-cell responses against autologous antigens derived from the transfected mRNA. 25 The clinical trial results reported here demonstrate that tDCspecific T-cell responses can also be induced in vivo. Notably, the trial was conducted on patients with advanced metastatic melanoma; at inclusion 21/22 patients had stage IV disease and 16/22 patients M1C disease. To elicit immune responses, the vaccine would have to overcome both tumor-tolerance and general immuno-suppression, induced by the disease or by previous treatment. A vaccine-generated tDC-specific response was still detected in about 50% of the trial patients (Table 3) , and no serious adverse advents were observed. The clinical trial demonstrated that the applied vaccination program, including preparation of individualized vaccines, is feasible and safe.
As reported, we repeatedly observed T-cell responses even to mockDCs after vaccination, both in the in vitro T-cell assays and in the DTH-reactions. A similar response was also generated by in vitro stimulations in our preclinical evaluation. 25 In contrast, there are few reports on such responses in previous DC-vaccine trials. However, in most trials, the reactivity to unloaded DCs have not been measured in the in vitro T-cell assays 10, 21, 22, [31] [32] [33] or have been measured in cytotox-assays only. 14, 26 Further, some trials have made use of immature DCs. 18, [27] [28] [29] Interestingly, responses to unloaded matured DCs were recently published in a lung cancer DC vaccine trial. 34 The mockDC-response in our melanoma trial may represent an autologous mixed lymphocyte reaction (AMLR). Dendritic cells, preferentially of a mature phenotype, are considered to be the prime initiators of such responses. 35, 36 Alternatively, the responding T cells may recognize foreign antigens engulfed during ex vivo DC-generation. As no serum was added in our protocol, the candidate antigens would be derived from supplemented cytokines, like GM-CSF, 37 or proteins in the Cellgro DC-medium. Regardless of the nature of the mockDC-antigens recognized, the responding T cells may exert an important regulatory influence on the tDCspecific response.
The considerable mockDC-responses tended to obscure the tDC-specific responses. Nevertheless, a significantly higher T-cell proliferation to tDCs was demonstrated for 10/19 patients tested (Figure 2a) . As a booster effect of the vaccine was demonstrated in 2/3 patients with prevaccine responses, 9/19 patients were considered vaccine responders based on the T-cell proliferation assays (Table 3) . We observed a strong correlation between the proliferation and IFNg ELISPOT results. tDC-specific IFNg-secretion was demonstrated in all four ELISPOT assays that were conducted on cells responding by T-cell proliferation (Figure 3a-d) . In contrast, only one of the other ELISPOT-assays was positive (Figure 3e) . Furthermore, the DTH-reactions correlated well with the in vitro T-cell assays. Delayed-type hypersensitivity measurements were performed for 7 of the patients classified as vaccine responders in the proliferation assays, and for seven proliferation nonresponders. A tDC-specific DTH reaction, generated by the vaccine, was demonstrated in 6/7 proliferation responders, as opposed to 0/7 proliferation nonresponders.
The interpretation and comparison of several previous trials have been difficult because of sparse information on individual variations in DC viability, phenotype, etc. 38 In the clinical trial reported here, the DC viability immediately before injection was homogeneously high (Table 1) . Regarding the DC phenotype, we noted considerable interpatient variation in the DC expression of maturation marker CD83 (Table 1) . However, the results did not indicate any correlation between the CD83 þ fraction and the probability of an immune response (P ¼ 0.85). This could be due to the high number of DCs injected, or reflect considerable APC-capacity even in the CD83 À immature DC population. Importantly, the nature of the immune response can still have been affected. CD83 À DC-like cells are generally assumed to induce more tolerogenic and Th2-type responses. We aim to determine whether this applies to our DC-vaccine by use of extensive cytokine profile characterization in future trials.
The results did not demonstrate a significant correlation between the mRNA concentration at transfection and the probability for a vaccine response (P ¼ 0.57; Table 1 ). A moderate correlation may though not have been revealed due to the limited number of evaluated patients. Excluding the two patients regarded not conclusive, a response was obtained in 3/4 patients with mRNA concentrations X48 mg/ml compared to 3/10 patients with concentrations p48 mg/ml. However, the immune response obtained for patient M07 demonstrate that, with the applied method of transfection, even low mRNA concentrations (8 mg/ml) may result in detectable responses. The finding suggests that small tumors, as usually found in less advanced patients, could be sufficient for generating responses by the described vaccine. The observation is of particular interest as we plan new trials on stage III patients.
Several studies have shown that only a small fraction of injected DCs reach the regional lymph node after i.d. injection. 39, 40 In a recent vaccine study, based on DCs loaded with allogenic melanoma lysates, Salcedo et al. 12 applied both i.n., i.d. and subcutaneous vaccine administration. In the present trial, we studied the feasibility, safety and effect of i.n. injection, and also compared the method to i.d. vaccination. All 48 i.n. injections (12 patients Â 4) were successful, as monitored by ultrasound, and no clinically important complications were observed. Accordingly, the i.n. vaccination appears to be feasible and safe, though certain technical expertise is required. The results further demonstrate that in vivo tDC-specific immune responses can be induced by both i.d. and i.n. vaccine administration. The observed higher success ratio for i.d. injection may reflect that this method is more effective, but the number of patients is too small for any firm conclusions. Interestingly, we observed similar results in a vaccine trial on prostate cancer, performed in parallel with the melanoma trial. Immune responses were detected in 8/9 prostate cancer patients vaccinated i.d. and 4/10 patients vaccinated i.n. 11 In the prostate trial, the DCs were transfected with tumor RNA from allogenic cell lines, but the methods for DC-generation and vaccine administration were similar to the melanoma trial. Certain factors may favor i.d. injection in our protocols. First, due to the high number of DCs/batch (20 Â 10 6 ), even a small fraction of successfully migrating DCs could be sufficient. Second, the successfully migrating DCs after i.d. injection will be a selected DC population, which may also receive further maturation signals during migration. Third, the lymph node architecture may be disrupted by i.n. injections. This last point was in our view a prime a priori concern. The ultrasound monitoring, however, demonstrated retained lymph node macro-architecture. Furthermore, the measured increase of the cortex/paracortex region ( Figure 1) indicates that T-cell stimulation by the injected tDCs indeed took place in this lymph node compartment, which is specialized for APC-T-cell interactions.
As described, we have chosen DCs electroporated without RNA as control APCs. This is a conventional approach, as most assays for antigen specificity compares the T-cell response to APCs with or without antigen. In our full-scale vaccine preparations, the amount of tumor-mRNA entering the DCs at electropration will be minute compared to the endogeneous mRNA present. Regarding antigens that are expressed both in monocytes/ DCs and in tumor tissue, we therefore consider the mockDCs to be adequate controls. The mockDCs were also logistically available, and did not differ from the tDCs with regard to phenotype or viability. Alternatively, we might have applied control DCs that had been transfected with a selected control RNA. However, appropriate tissues for control RNA are not readily available. Normal skin includes tissue specific antigens highly relevant for an anti-melanoma response. PBMC-RNA would only provide a limited extension of the spectrum of antigens, compared to the monocyte-derived mockDCs. Autologous fibroblast-RNA would be a better control, but is not readily available. Regardless of the choice of controls, the essential point is not to overinterpret the finding of tDC-specific responses. In addition to antigens expressed by the tumor cells, the transfected mRNA will encode tumor-associated and other antigens expressed by stromal, endothelial and infiltrating cells in the tumor.
In the present trial, the nature of the transfected antigens recognized is not known. This is an inherent consequence of the complete tumor-mRNA strategy. We have focused on establishing an individualized therapy, rather than identifying or studying common tumor antigens. Importantly, we know that the antigens recognized are expressed in the autologous tumors. Moreover, the tDC-specific responses observed in prevaccination samples strongly suggest that three patients had been spontaneously primed to antigens encoded by the transfected mRNA. This observation indicates that the vaccine includes antigens that are relevant to the antitumor immune response.
The Bioplex assays demonstrated secretion of a wide spectrum of cytokines (Table 2) , a finding that may reflect priming by different DC subtypes. As mentioned above, the DCs consisted of a CD83 þ and a CD83 À subset, and different DC-subtypes may induce different polarization of the T-cell response. 41, 42 The tDC-specific secretion of IFNg and TNFa, detected in M05-cultures, suggest that some of the responding T cells belong to the Th1 subtype and may provide an effective antitumor response. A Th2-type response is generally not desirable for tumor eradication, and Th2-associated cytokines IL-5 and IL-13 were detected for all three patients. However, as IL-4 and IL-10 were not detected, the implications of the unconventional Th2-profile observed are not clear. Notably, current experience from humans is to a large extent based on studies where the Th1-or Th2-profiles have been determined by use of only IFNg and IL-4/ IL-10. Moreover, among the Th2-like cytokines, IL-10 is most strongly associated with tumor-tolerance and regarded as the primary cytokine secreted by regulatory T cells. It was conceivable that part of the proliferation detected in the proliferation assays could be due to IL10-secreting regulatory T cells, although their proliferation capacity is generally limited. This seems not to be the case since IL-10 was not detected in the supernatants, and tDC-specific proliferation was observed for all the T-cell populations tested by Bioplex. As reported, the supernatant assays demonstrated high levels of chemokines MIP-1b and MCP-1, known to be potent chemoattractors of T cells and monocytes. 43, 44 Monocyte chemoattractant protein-1 have been associated both with a favorable cancer prognosis and with aggressive tumor progression. 45, 46 In a study on melanoma xenografts, low-level MCP-1 secretion by melanoma cells facilitated tumor formation, while high-level MCP-1 secretion induced tumor destruction. 47 T cells responding to mockDCs may secrete cytokines that influence the Th1/Th2-polarization of the tDCspecific response, particularly as both subsets of responding T cells are initially stimulated in the same lymph nodes. We observed that T-cell stimulation by mockDCs induced secretion of high amounts of MIP-1b and MCP-1 and varying amounts of IL-5 and IL-13, but no IL-4 or IL-10 ( Table 2 ). For patient M05 was further detected TNFa and IFNg. Thus, the cytokine profiles closely resembled what was observed for the tDC-specific response.
The story of cancer immunotherapy clearly demonstrates the challenge in making immune responses effective. In particular, it may be important to control the phenotype/function of the vaccine DCs and to counteract the tolerogenic activity of regulatory T cells. It is desirable to avoid secretion by vaccine DCs of TGFb and IL-10, which may prevent Th1 differentiation and promote production of IL-10/TGFb secreting regulatory T cells. Recent knowledge on siRNA provides an attractive option for regulating the DC functionality. In an ongoing preclinical evaluation, DCs are co-transfected with tumor RNA/standard antigen RNA (hTERT) and siRNA for TGFb and IL-10. In future trials, we will moreover consider depleting the CD4 þ CD25 þ regulatory T cells by use of an immunotoxin specific for CD25 48 or a IL-2 toxin conjugate. 49 Currently, in an ongoing clinical trial, we investigate the effects of preconditioning with chemotherapy prior to peptide vaccination. This approach may also function to counter regulatory T cells. 50 In the present trial, the mean survival of the major prognostic group, the M1C group, was 12.3 months from disease progression and 8.1 months from the start of the vaccination. The mean survival for the age-matched M1C reference group was 5.8 months, calculated from disease progression. These data demonstrate that the M1C patients in the trial survived longer than the nonvaccinated M1C patients receiving standard treatment at the hospital. The phase I/II study design does, however, not allow for any firm conclusions on clinical effect. There is no basis for concluding that the observed survival difference was caused by the vaccine therapy. It should also be recalled that for the majority of patients included in the trial, the vaccine did not substantially alter the clinical course of the disease. Interestingly, we have though to date observed prolonged survival 420 months in 4/10 vaccine immune responders compared to 0/10 nonresponders (Table 3) . In patient M03, we detected both objective regression of certain tumors and a strong and sustained tDC-specific immune response demonstrated both in T-cell assays and DTH measurements. Moreover, the patient survived for 23 months, despite visceral metastases at study entry. Due to the limited number of patients, we can however not draw any general conclusion on a correlation between immune responses and survival.
The reported vitiligo and pain/inflammation in tumor provide indications of a biological in vivo effect of the vaccine. Except for the vitiligo reaction (one patient), no autoimmune adverse effects were observed. This is of particular interest as a wide array of autoantigens will be included in the vaccine. As the results demonstrate that the vaccine is safe, we plan to conduct a clinical trial in patients with less advanced melanoma disease. The prospect of clinical benefit may be better in patients with less tumor burden, no visceral metastases and a less suppressed immune system.
We conclude that therapy with the described individualized DC-vaccine is feasible and safe. Further, detectable T-cell responses, specific for antigens encoded by the transfected autologous tumor-mRNA, are induced in about 50% of the vaccinated patients. Both i.d. and i.n. vaccine injection function to elicit immune responses. The response rates observed do not suggest an advantage in applying i.n. injection. In our view the results of the present trial, the first melanoma vaccine trial utilizing complete tumor-mRNA as the source of antigen, are encouraging. However, further investigations are needed to optimize the vaccine protocol, and more extensive trials will be required to study the question of clinical benefit.
